

Xavier MartÃ- nez-GÃ³mez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9375972/publications.pdf>

Version: 2024-02-01

9
papers

210
citations

1307366

7
h-index

1372474

10
g-index

11
all docs

11
docs citations

11
times ranked

397
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. <i>Infection</i> , 2021, 49, 215-231.	2.3	63
2	Asymptomatic SARS-CoV-2 Infection in Nursing Homes, Barcelona, Spain, April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2281-2283.	2.0	45
3	<i>Mycoplasma genitalium</i> and antimicrobial resistance in Europe: a comprehensive review. <i>International Journal of STD and AIDS</i> , 2020, 31, 190-197.	0.5	40
4	Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 92-98.	1.4	28
5	Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season. <i>Drug Safety</i> , 2020, 43, 265-279.	1.4	9
6	Vacunas para pacientes en tratamiento con fármacos inmunodepresores, inmunomoduladores o biológicos. <i>Medicina Clínica</i> , 2018, 151, 498-502.	0.3	8
7	Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection. <i>Vaccines</i> , 2021, 9, 1463.	2.1	8
8	Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season. <i>Drug Safety</i> , 2021, 44, 1375-1390.	1.4	5
9	Brand-Specific Enhanced Safety Surveillance Study of GSK's Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season. <i>Infectious Diseases and Therapy</i> , 2022, 11, 463-483.	1.8	3